BioCryst Pharma (BCRX) Tops Q2 EPS by 11c, provides product guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies
August 5, 2024 4:01 PM EDTJefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $11.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "Focus heading into 2Q was on Orladyo sales, and BCRX delivered another commercial surprise (stock +5.5%) and increased guidance due to... More
